Skip to main content

Webinars

  • Mark Flood, BMLSc ,
    Application Specialist, Pathology Associates, Pathlab Bay of Plenty, New Zealand

Are you looking to adopt digital pathology in your organization? Learn how an integrated approach can help support digital pathology adoption across clinical, research, and educational workflows.

The Value of a Ready-To-Use Antibody presented by Chris Rhodes of Leica Biosystems. An RTU in a clinical setting is defined as able to dispense with minimal, if any, effort or preparation. It is important to remember this definition. Ready-to-use products offer many advantages, including the removal of variability of quality, which naturally will occur when a user is required to prepare a reagent.

Novocastra p16 antibody demonstrated an agreement of 98% with the Roche p16 antibody The study compared the percentage agreement rates of Novocastra’s p16 (6H12) IVD solution with Roche CINtec® Histology p16 assay on 170 oropharyngeal cancer cases.